Drug intelligence / Profile preview

SM360320

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

SM360320, also known as CL-087, is a potent, orally active, and selective Toll-like receptor 7 (TLR7) agonist. It induces the secretion of interferon alpha (IFN-α) and has been shown to inhibit hepatitis C virus (HCV) replication in hepatocytes. SM360320 acts through both interferon-dependent and -independent mechanisms, enhancing antiviral effects when combined with IMPDH inhibitors. It is also explored for its potential in treating autoimmune inflammation and cancer due to its immunomodulatory properties[1][2][3].

Other names: 9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on SM360320.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM360320.

Explore the full profile